Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of Streptococcus pneumoniae from US Medical Centers

Página do item simplificado
dc.contributor.authorFlamm, Robert K.
dc.contributor.authorSader, Helio S. [UNIFESP]
dc.contributor.authorFarrell, David J.
dc.contributor.authorJones, Ronald N.
dc.contributor.institutionJMI Labs
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniv Toronto
dc.contributor.institutionTufts Univ
dc.date.accessioned2016-01-24T14:35:29Z
dc.date.available2016-01-24T14:35:29Z
dc.date.issued2014-04-01
dc.description.abstractStreptococcus pneumoniae isolates (6,958) were collected from patients at 163 U. S. medical centers during 2009 through 2012. Isolates were evaluated for multidrug resistance (MDR) to penicillin, ceftriaxone, erythromycin, tetracycline, trimethoprimsulfamethoxazole, and levofloxacin. Ceftaroline was 16-fold more potent than ceftriaxone (MIC50/MIC90, <= 0.25/2 mu g/ml) against all isolates. for MDR isolates (35.2% of tested strains), ceftaroline (MIC50/MIC90, 0.06/0.25 mu g/ml; 100.0% susceptible) was the most active agent tested, being 8-fold more potent than ceftriaxone (MIC50/MIC90, 0.5/2 mu g/ml) and 16-fold more potent than penicillin (MIC50/MIC90, 1/4 mu g/ml).en
dc.description.affiliationJMI Labs, North Liberty, IA 52317 USA
dc.description.affiliationUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, Brazil
dc.description.affiliationUniv Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipForest/Cerexa
dc.description.sponsorshipAchaogen
dc.description.sponsorshipAires
dc.description.sponsorshipAmerican Proficiency Institute (API)
dc.description.sponsorshipAnacor
dc.description.sponsorshipAstellas
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipbioMerieux
dc.description.sponsorshipCempra
dc.description.sponsorshipCerexa
dc.description.sponsorshipContrafect
dc.description.sponsorshipCubist
dc.description.sponsorshipDipexium
dc.description.sponsorshipEnanta
dc.description.sponsorshipFuriex
dc.description.sponsorshipGlaxoSmithKline
dc.description.sponsorshipJohnson Johnson
dc.description.sponsorshipLegoChem Biosciences Inc.
dc.description.sponsorshipMeiji Seika Kaisha
dc.description.sponsorshipNabriva
dc.description.sponsorshipNovartis
dc.description.sponsorshipPfizer
dc.description.sponsorshipPPD Therapeutics
dc.description.sponsorshipPremier Research Group
dc.description.sponsorshipRempex
dc.description.sponsorshipRib-X Pharmaceuticals
dc.description.sponsorshipSeachaid
dc.description.sponsorshipShionogi
dc.description.sponsorshipThe Medicines Co.
dc.description.sponsorshipTheravance
dc.description.sponsorshipThermoFisher
dc.format.extent2468-2471
dc.identifierhttp://dx.doi.org/10.1128/AAC.02557-13
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Washington: Amer Soc Microbiology, v. 58, n. 4, p. 2468-2471, 2014.
dc.identifier.doi10.1128/AAC.02557-13
dc.identifier.fileWOS000333605600086.pdf
dc.identifier.issn0066-4804
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/37579
dc.identifier.wosWOS:000333605600086
dc.language.isoeng
dc.publisherAmer Soc Microbiology
dc.relation.ispartofAntimicrobial Agents and Chemotherapy
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleAntimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of Streptococcus pneumoniae from US Medical Centersen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000333605600086.pdf
Tamanho:
108.95 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
Em verificação - Geral